Targeting retroviral and lentiviral vectors

Current Topics in Microbiology and Immunology

Volumn 281, Issue , 2003, Pages 137-178

  Sandrin, V ^a   Russell, S J ^b   Cosset, F L ^a  

^a UNIVERSITÉ DE LYON   (France)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; LENTIVIRUS VECTOR; PROTEINASE; RETROVIRUS VECTOR; VIRUS FUSION PROTEIN; VIRUS GLYCOPROTEIN; VIRUS VECTOR;

GENE TARGETING; GENE THERAPY; GENE TRANSFER; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN TARGETING; RECEPTOR BINDING; REVIEW; STRUCTURE ACTIVITY RELATION; TARGET CELL; VIRAL GENE DELIVERY SYSTEM; VIRUS ADSORPTION; VIRUS CELL INTERACTION; VIRUS ENVELOPE; VIRUS TYPING;

LENTIVIRUS; UNIDENTIFIED RETROVIRUS;

EID: 0042665422     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-19012-4_4     Document Type: Review

References (173)

1. Abe A, Chen ST, Miyanohara A, and Friedmann T (1998) In vitro cell-free conversion of noninfectious Moloney retrovirus particles to an infectious form by the addition of the vesicular stomatitis virus surrogate envelope G protein. J Virol 72:6356-61
2. Ager S, Nilson BHK, Morling FJ, Peng KW, Cosset F-L, and Russell SJ (1996) Retroviral display of antibody fragments; interdomain spacing strongly influences vector infectivity. Hum Gene Ther 7:2157-2164
3. Barnett AL, and Cunningham JM (2001) Receptor binding transforms the surface subunit of the mammalian C-type retrovirus envelope protein from an inhibitor to an activator of fusion. J Virol 75:9096-105
4. Barnett AL, Davey RA, and Cunningham JM (2001) Modular organization of the Friend murine leukemia virus envelope protein underlies the mechanism of infection. Proc Natl Acad Sci U S A 98:4113-8
5. Bartosch B, Dubuisson J, Cosset FL (2003) Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 197:633-42
6. Battini JL, Danos O, and Heard JM (1998) Definition of a 14-amino-acid peptide essential for the interaction between the murine leukemia virus amphotropic envelope glycoprotein and its receptor. J Virol 72:428-435
7. Benedict CA, Tun RY, Rubinstein DB, Guillaume T, Cannon PM, and Anderson WF (1999) Targeting retroviral vectors to CD34-expressing cells: binding to CD34 does not catalyze virus-cell fusion. Hum Gene Ther 10:545-557
8. Beyer WR, Westphal M, Ostertag W, and ron von Laer D (2002) Oncoretrovirus and lentivirus vectors pseudotyped with lymphocytic choriomeningitis virus glycoprotein: generation, concentration, and broad host range. J Virol 76:1488-95
9. Bobkova M, Stitz J, Engelstadter M, Cichutek K, and Buchholz CJ (2002) Identification of R-peptides in envelope proteins of C-type retroviruses. J Gen Virol 83:2241-6
10. Boerger AL, Snitkovsky S, and Young JA (1999) Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types. Proc Natl Acad Sci U S A 96:9867-72
11. Bounou S, Leclerc JE, and Tremblay MJ (2002) Presence of host ICAM-1 in laboratory and clinical strains of human immunodeficiency virus type 1 increases virus infectivity and CD4(+)-T-cell depletion in human lymphoid tissue, a major site of replication in vivo. J Virol 76:1004-14
12. Brody BA, Rhee SS, and Hunter E (1994) Postassembly cleavage of a retroviral glycoprotein cytoplasmic domain removes a necessary incorporation signal and activates fusion activity. J Virol 68:4620-4627
13. Buchholz CJ, Peng K-W, Morling FJ, Zhang J, Cosset F-L, and Russell SJ (1998) In vivo selection of protease cleavage sites from retrovirus display libraries. Nat Biotechnol 16:951-954
14. Bupp K, and Roth MJ (2002) Altering retroviral tropism using a random-display envelope library. Mol Ther 5:329-35
15. Burns JC, Friedmann T, Driever W, Burrascano M, and Yee JK (1993) Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci U S A 90:8033-8037
16. Carr CM, Chaundhry C, and Kim PS (1997) Influenza hemagglutinin is spring-loaded by a metastable native conformation. Proc Natl Acad Sci USA 23:14306-14313
17. Cavazzana-Calvo M, Hacein-Bey S, Basile GdS, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova J, Bousso P, Deist F, and Fischer A (2000) Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288:669-672
18. Chadwick MP, Morling FJ, Cosset F-L, and Russell SJ (1999) Modification of retroviral tropism by display of IGF-I. J Mol Biol 285:485-494
19. Chen J, Lee KH, Steinhauer DA, Stevens DJ, Skehel JJ, and Wiley DC (1998) Structure of the hemagglutinin precursor cleavage site, a determinant of influenza pathogenicity and the origin of the labile conformation. Cell 95:409-417
20. Chester J, Ruchatz A, Gough M, Crittenden M, Chong H, Cosset F-L, Diaz RM, Harrington K, Alvarez-Vallina L, and Vile R (2002) Tumor antigen-specific induction of transcriptionally targeted retroviral vectors from chimeric immune receptor-modified T cells. Nat Biotechnol 20:256-263
21. Christodoulopoulos I, and Cannon P (2001) Sequences in the cytoplasmic tail of the gibbon ape leukemia virus envelope protein that prevent its incorporation into lentivirus vectors. J Virol 75:4129-38
22. Chu THT, and Dornburg R (1995) Retroviral vector particles displaying the antigen-binding site of an antibody enable cell-type-specific gene transfer. J. Virol. 69:2659-2663
23. Chu THT, Martinez I, Sheay WC, and Dornburg R (1994) Cell targeting with retroviral vector particles containing antibody-envelope fusion proteins. Gene Therapy 1:292-299
24. Cosset F-L, Morling FJ, Takeuchi Y, Weiss RA, Collins MKL, and Russell SJ (1995) Retroviral retargeting by envelopes expressing an N-terminal binding domain. J. Virol. 69:6314-6322
25. Cosson P (1996) Direct interaction between the envelope and matrix proteins of HIV-1. EMBO J. 15:5783-5788
26. DePolo NJ, Reed JD, Sheridan PL, Townsend K, Sauter SL, Jolly DJ, and Dubensky TW (2000) VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum. Mol Ther 2:218-22
27. Desmaris N, Bosch A, Salaun C, Petit C, Prevost MC, Tordo N, Perrin P, Schwartz O, deRocquigny H, and Heard JM (2001) Production and neurotropism of lentivirus vectors pseudotyped with lyssavirus envelope glycoproteins. Mol Ther 4:149-56
28. Dong J, Roth MG, and Hunter E (1992) A chimeric avian retrovirus containing the influenza virus hemagglutinin gene has an expanded host range. J Virol 66:7374-7382
29. Duisit G, Conrath H, Saleun S, Folliot S, Provost N, Cosset F-L, Sandrin V, Moullier P, and Rolling F (2002) Five recombinant SIV pseudotypes lead to exclusive transduction of retinal pigmented epithelium in rat. Mol Ther. In press
30. Engelstadter M, Bobkova M, Baier M, Stitz J, Holtkamp N, Chu TH, Kurth R, Dornburg R, Buchholz CJ, and Cichutek K (2000) Targeting human T cells by retroviral vectors displaying antibody domains selected from a phage display library. Hum Gene Ther 11:293-303
31. Engelstadter M, Buchholz CJ, Bobkova M, Steidl S, Merget-Millitzer H, Willemsen RA, Stitz J, and Cichutek K (2001) Targeted gene transfer to lymphocytes using murine leukaemia virus vectors pseudotyped with spleen necrosis virus envelope proteins. Gene Ther 8:1202-6
32. Etienne-Julan M, Roux P, Carillo S, Jeanteur P, and Piechaczyk M (1992) The efficiency of cell targeting by recombinant retroviruses depends on the nature of the receptor and the composition of the artificial cell-virus linker. J. Gen. Virol. 73:3251-3255
33. Erlwein O, Buchholz CJ, Schnierle BS (2003) The proline-rich region of the ecotropic Moloney murine leukaemia virus envelope protein tolerates the insertion of the green fluorescent protein and allows the generation of replication-competent virus. J Gen Virol 84:369-373
34. Erlwein O, Wels W, Schnierle BS (2002) Chimeric ecotropic MLV envelope proteins that carry EGF receptor-specific ligands and the Pseudomonas exotoxin A translocation domain to target gene transfer to human cancer cells. Virology 302:333-341
35. Fass D, Davey RA, Hamson CA, Kim PS, Cunningham JM, and Berger JM (1997) Structure of a murine leukemia virus receptor-binding glycoprotein at 2.0 angstrom resolution. Science 277:1662-1666
36. Fielding A, Chapel-Fernandes S, Chadwick M, Bullough F, Cosset F-L, and Russell S (2000) A hyperfusogenic gibbon ape leukemia virus envelope glycoprotein: targeting of a cytotoxic gene by ligand display. Hum Gene Ther 11:817-826
37. Fielding AK, Maurice M, Morling FJ, Cosset F-L, and Russell SJ (1998) Inverse targeting of retroviral vectors: selective gene transfer in a mixed population of hematopoietic and nonhematopoietic cells. Blood 91:1802-1809
38. Fortin JF, Cantin R, Bergeron MG, and Tremblay MJ (2000) Interaction between virion-bound host intercellular adhesion molecule-1 and the high-affinity state of lymphocyte function-associated antigen-1 on target cells renders R5 and X4 isolates of human immunodeficiency virus type 1 more refractory to neutralization. Virology 268:493-503
39. Fortin JF, Cantin R, Lamontagne G, and Tremblay M (1997) Host-derived ICAM-1 glycoproteins incorporated on human immunodeficiency virus type 1 are biologically active and enhance viral infectivity. J Virol 71:3588-3596
40. Freed EO (1998) HIV-1 gag proteins: diverse functions in the virus life cycle. Virology 251:1-15
41. Gautier R, Jiang A, Rousseau V, Dornburg R, and Jaffredo T (1999) Avian reticuloendotheliosis virus strain A and spleen necrosis virus do not infect human cells. J Virol 74:518-522
42. Gollan TJ, and Green MR (2002a) Redirecting retroviral tropism by insertion of short, nondisruptive peptide ligands into envelope. J Virol 76:3558-63
43. Gollan TJ, and Green MR (2002b) Selective targeting and inducible destruction of human cancer cells by retroviruses with envelope proteins bearing short peptide ligands. J Virol 76:3564-9
44. Gordon EM, Chen ZH, Liu L, Whitley M, Liu L, Wei D, Groshen S, Hinton DR, Anderson WF, Beart RW, and Hall FL (2001a) Systemic administration of a matrix-targeted retroviral vector is efficacious for cancer gene therapy in mice. Hum Gene Ther 12:193-204
45. Gordon EM, Zhu NL, Forney-Prescott M, Chen ZH, Anderson WF, and FL FLH (2001b) Lesion-targeted injectable vectors for vascular restenosis. Hum Gene Ther 12:1277-87
46. Goud B, Legrain P, and Buttin G (1988) Antibody-mediated binding of a murine ecotropic Moloney retroviral vector to human cells allows internalization but not the establishment of the proviral state. Virology 163:251-254
47. Hall FL, Gordon EM, Wu L, Zhu NL, Skotzko MJ, Starnes VA, and Anderson WF (1997) Targeting retroviral vectors to vascular lesions by genetic engineering of the MoMLV gp70 envelope protein. Hum Gene Ther 8:2183-2192
48. Hall FL, Liu L, Zhu NL, Stapfer M, Anderson WF, Beart RW, and Gordon EM (2000) Molecular engineering of matrix-targeted retroviral vectors incorporating a surveillance function inherent in von Willebrand factor. Hum Gene Ther 11:983-93
49. Han X, Kasahara N, and Kan YW (1995) Ligand-directed retroviral targeting of human breast cancer cells. Proc Natl Acad Sci USA 92:9747-9751
50. Hanawa H, Kelly PF, Nathwani AC, Persons DA, Vandergriff JA, Hargrove P, Vanin EF, and Nienhuis AW (2002) Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hematopoietic cells from human blood. Mol Ther 5:242-51
51. Hatziioannou T, Delahaye E, Martin F, Russell SJ, and Cosset F-L (1999) Retroviral display of functional binding domains fused to the amino-terminus of influenza haemagglutinin. Hum Gene Ther 10:1533-1544
52. Hatziioannou T, Valsesia-Wittmann S, Russell S, and Cosset F-L (1998) Incorporation of fowl plague virus hemagglutinin into murine leukemia virus particles and analysis of the infectivity of the pseudotyped retroviruses. J Virol 72:5313-5317
53. Hatziioannou T, Russell SJ, and Cosset F-L (2000) Incorporation of simian virus 5 fusion protein into murine leukemia virus particles and its effect on the co-incorporation of retroviral envelope glycoproteins. Virology 267:49-57
54. Hughson FM (1997) Enveloped viruses: a common mode of membrane fusion? Curr Biol 7:R565-9
55. Hunter E (1997) Viral entry and receptors. In "Retroviruses" (J M Coffin, S H Hughes and H E Varmus, eds.), pp. 71-120. Cold Spring Harbor Laboratory Press, New York, USA
56. Innes CL, Smith PB, Langenbach R, Tindall KR, and Boone LR (1990) Cationic liposomes (Lipofectin) mediate retroviral infection in the absence of specific receptors. J Virol 64:957-61
57. Jiang A, Chu TH, Nocken F, Cichutek K, and Dornburg R (1998) Cell-type-specific gene transfer into human cells with retroviral vectors that display single-chain antibodies. J Virol 72:10148-10156
58. Jiang A, and Dornburg R (1999) In vivo cell type-specific gene delivery with retroviral vectors that display single chain antibodies. Gene Ther 6:1982-7
59. Kang Y, Stein CS, Heth JA, Sinn PL, Penisten AK, Staber PD, Ratliff KL, Shen H, Barker CK, Martins I, Sharkey CM, Sanders DA, McCray PB, Jr., and Davidson BL (2002) In vivo gene transfer using a nonprimate lentiviral vector pseudotyped with Ross River Virus glycoproteins. J Virol 76:9378-88
60. Katane M, Takao E, Kubo Y, Fujita R, Amanuma H (2002) Factors affecting the direct targeting of murine leukemia virus vectors containing peptide ligands in the envelope protein. EMBO Rep 3:899-904
61. Kasahara N, Dozy AM, and Kan YW (1994) Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science 266:1373-1376
62. Kayman SC, Park H, Saxon M, and Pinter A (1999) The hypervariable domain of the murine leukemia virus surface protein tolerates large insertions and deletions, enabling development of a retroviral particle display system. J Virol 73:1802-1808
63. Kelly P, Vandergriff J, Nathwani A, Nienhuis A, and Vanin E (2000) Highly efficient gene transfer into cord blood nonobese diabetic/severe combined immunodeficiency repopulating cells by oncoretroviral vector particles pseudotyped with the feline endogenous retrovirus (RD 114) envelope protein. Blood 96:1206-1214
64. Khare PD, Shao-Xi L, Kuroki M, Hirose Y, Arakawa F, Nakamura K, Tomita Y, and Kuroki M (2001) Specifically targeted killing of carcinoembryonic antigen (CEA)-expressing cells by a retroviral vector displaying single-chain variable fragmented antibody to CEA and carrying the gene for inducible nitric oxide synthase. Cancer Res 61:370-5
65. Kobe B, Center RJ, Kemp BE, and Poumbourios P (1999) Crystal structure of human T cell leukemia virus type 1 gp21 ectodomain crystallized as a maltose-binding protein chimera reveals structural evolution of retroviral transmembrane proteins. Proc Natl Acad Sci USA 96:4319-4324
66. Kobinger GP, Weiner DJ, Yu QC, and Wilson JM (2001) Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo. Nat Biotechnol 19:225-30
67. Konishi H, Ochiya T, Chester KA, Begent RH, Muto T, Sugimura T, and Terada M (1998) Targeting strategy for gene delivery to carcinoembryonic antigen-producing cancer cells by retrovirus displaying a single-chain variable fragment antibody. Hum Gene Ther 9:235-248
68. Lamb RA (1993) Paramyxovirus fusion: A hypothesis for changes. Virology 197:1-11
69. Lavillette D, Boson B, Russell S, and Cosset F-L (2001a) Membrane fusion by murine leukemia viruses is activated in cis or in trans by interactions of the receptor-binding domain with a conserved disulfide loop at the carboxy-terminus of the surface glycoproteins. J Virol 75:3685-3695
70. Lavillette D, Maurice M, Roche C, Russell SJ, Sitbon M, and Cosset F-L (1998) A proline-rich motif downstream of the receptor binding domain modulates conformation and fusogenicity of murine retroviral envelopes. J Virol 72:9955-9965
71. Lavillette D, Ruggieri A, Boson B, Maurice M, and Cosset F-L (2002) Relationship between SU subdomains that regulate the receptor-mediated transition from the native (fusion-inhibited) and fusion-active conformations of the murine leukemia virus glycoprotein. J Virol 76:9685-2002
72. Lavillette D, Ruggieri A, Russell SJ, and Cosset F-L (2000) Activation of a cell entry pathway common to type C mammalian retroviruses by soluble envelope fragments. J Virol 74:295-304
73. Lavillette D, Russell SJ, and Cosset F-L (2001b) Retargeting gene delivery by surface-engineered retroviral vector particles. Curr Opin Biotechnol 12:461-466
74. Lee S, Zhao Y, and Anderson WF (1999) Receptor-mediated moloney murine leukemia virus entry can occur independently of the clathrin-coated-pit-mediated endocytic pathway. J Virol 73:5994-6005
75. Lin AH, Kasahara N, Wu W, Stripecke R, Empig CL, Anderson WF, and Cannon PM (2001) Receptor-specific targeting mediated by the coexpression of a targeted murine leukemia virus envelope protein and a binding-defective influenza hemagglutinin protein. Hum Gene Ther 12:323-32
76. Lindemann D, Bock M, Schweizer M, and Rethwilm A (1997) Efficient pseudotyping of murine leukemia virus particles with chimeric human foamy virus envelope proteins. J. Virol 71:4815-4820
77. Linder M, Linder D, Hahnen J, Schott HH, and Stirm S (1992) Localization of the intrachain disulfide bonds of the envelope glycoprotein 71 from Friend murine leukemia virus. Eur J Biochem 203:65-73
78. Linder M, Wenzel V, Linder D, and Stirm S (1994) Structural elements in glycoprotein 70 from polytropic Friend mink cell focus-inducing virus and glycoprotein 71 from ecotropic Friend murine leukemia virus, as defined by disulfide-bonding pattern and limited proteolysis. J Virol 68:5133-5141
79. Liu L, Anderson WF, Beart RW, Gordon EM, and Hall FL (2000) Incorporation of tumor vasculature targeting motifs into moloney murine leukemia virus env escort proteins enhances retrovirus binding and transduction of human endothelial cells. J Virol 74:5320-8
80. Lodge R, Subbramanian RA, Forget J, Lemay G, and Cohen EA (1998) MuLV-based vectors pseudotyped with truncated HIV glycoproteins mediate specific gene transfer in CD4+ peripheral blood lymphocytes. Gene Ther 5:655-64
81. Lorimer IA, and Lavictoire SJ (2000) Targeting retrovirus to cancer cells expressing a mutant EGF receptor by insertion of a single chain antibody variable domain in the envelope glycoprotein receptor binding lobe. J Immunol Methods 237:147-57
82. Mammano F, Salvatori F, Indraccolo S, de Rossi A, Chieco-Bianchi L, and Göttlinger HG (1997) Truncation of the human immunodeficiency virus type 1 envelope glycoprotein allows efficient pseudotyping of Moloney murine leukemia virus particles and gene transfer into CD4+ cells. J Virol 71:3341-3345
83. Marandin A, Dubart A, Pflumio F, Cosset F-L, Cordette V, Chapel-Fernandes S, Coulombel L, Vainchenker W, and Louache F (1998) Retroviral-mediated gene transfer into human CD34+/38- primitive cells capable of reconstituting long-term cultures in vitro and in nonobese diabetic-severe combined immunodeficiency mice in vivo. Human Gene Ther 9:1497-1511
84. Marechal V, Clavel F, Heard JM, and Schwartz O (1998) Cytosolic Gag p24 as an index of productive entry of human immunodeficiency virus type 1. J Virol 72: 2208-12
85. Marechal V, Prevost MC, Petit C, Perret E, Heard JM, and Schwartz O (2001) Human immunodeficiency virus type 1 entry into macrophages mediated by macropinocytosis. J Virol 75:11166-77
86. Marin M, Noël D, Valsesia-Wittmann S, Brockly F, Etienne-Julan M, Russell SJ, Cosset F-L, and Piechaczyk M (1996) Targeted infection of human cells via MHC class I molecules by MoMuLV-derived viruses displaying single-chain antibody fragment-envelope fusion proteins. J. Virol 70:2957-2962
87. Martin F, Chowdhury S, Neil S, Phillipps N, and Collins MK (2002) Envelope-targeted retrovirus vectors transduce melanoma xenografts but not spleen or liver. Mol Ther 5:269-74
88. Martin F, Kupsch J, Takeuchi Y, Russell S, Cosset F-L, and Collins M (1998) Retroviral vector targeting to melanoma cells by single-chain antibody incorporation in envelope. Hum Gene Ther 9:737-746
89. Martin F, Neil S, Kupsch J, Maurice M, Cosset F-L, and Collins M (1999) Retrovirus targeting by tropism restriction to melanoma cells. J Virol 73:6923-6929
90. Martin F, Chowdhury S, Neil SJ, Chester KA, Cosset F-L, and Collins MK (2003) Targeted retroviral infection of tumor cells by receptor cooperation. J Virol 77:2753-2756
91. Matano T, Odawara T, Iwamoto A, and Yoshikura H (1995) Targeted infection of a retrovirus bearing a CD4-Env chimera into human cells expressing human immunodeficiency virus type 1. J. Gen. Virol. 76:3165-3169
92. Maurice M, Mazur S, Bullough FJ, Salvetti A, Collins MKL, Russell SJ, and Cosset F-L (1999) Efficient gene delivery to quiescent IL2-dependent cells by murine leukemia virus-derived vectors harboring IL2 chimeric envelope glycoproteins. Blood 94:401-410
93. Maurice M, Verhoeyen E, Salmon P, Trono D, Russell SJ, and Cosset F-L (2002) Efficient gene transfer into human primary blood lymphocytes by surface-engineered lentiviral vectors that display a T cell-activating polypeptide. Blood 99:2342-50
94. McClure MO, Sommerfelt MA, Marsh M, and Weiss RA (1990) The pH independence of mammalian retrovirus infection. J. Gen. Virol. 71:767-773
95. Merten CA, Engelstaedter M, Buchholz CJ, Cichutek K (2003) Displaying epidermal growth factor on spleen necrosis virus-derived targeting vectors. Virology 305:106-114
96. Miletic H, Bruns M, Tsiakas K, Vogt B, Rezal R, Baum C, Kühlke K, Cosset F-L, Ostertag W, Lother H, and Laer DV (1999) Retroviral vectors pseudotyped with lymphocytic choriomeningitis virus. J Virol 73:6114-6116
97. Mochizuki H, Schwartz JP, Tanaka K, Brady RO, and Reiser J (1998) High-titer human immunodeficiency virus type 1-based vector systems for gene delivery into nondividing cells. J. Virol. 72:8873-8883
98. Mondor I, Ugolini S, and Sattentau QJ (1998) Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans. J Virol 1998:3623-34
99. Morizono K, Bristol G, Xie Y-M, Kung SK-P, and Chen ISC (2001) Antibody-directed targeting of retroviral vectors via cell surface antigens. J Virol 75:8016-8020
100. Morling FJ, Peng K-W, Cosset F-L, and Russell SJ (1997) Masking of retroviral envelope functions by oligomerizing peptide adaptors. Virology 234:51-61
101. Morrison TG (2001) The three faces of paramyxovirus attachment proteins. Trends Microbiol 9:103-5
102. Mothes W, Boerger AL, Narayan S, Cunningham JM, and Young JA (2000) Retroviral entry mediated by receptor priming and low pH triggering of an envelope glycoprotein. Cell 103:679-89
103. Movassagh M, Desmyter C, Baillou C, Chapel-Fernandes S, Guigon M, Klatzmann D, and Lemoine FM (1998) High-level gene transfer to cord blood progenitors using gibbon ape leukemia virus pseudotyped retroviral vectors and an improved clinically applicable protocol. Hum Gene Ther 9:225-234
104. Mukherjee S, Ghosh RN, and Maxfield FR (1997) Endocytosis. Physiol Rev 77:759-803
105. Murakami T, and Freed EO (2000) Genetic evidence for an interaction between human immunodeficiency virus type 1 matrix and alpha-helix 2 of the gp41 cytoplasmic tail. J Virol 74:3548-54
106. Naldini L, Blömer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, and Trono D (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263-267
107. Nègre D, Duisit G, Mangeot P-E, Moullier P, Darlix J-L, and Cosset F-L (2002) Lentiviral vectors derived from simian immunodeficiency virus (SIV). In "Current Topics in Microbiology and Immunology" (D Trono, ed.), pp. 53-74
108. Nègre D, Mangeot P, Duisit G, Blanchard S, Vidalain P, Leissner P, Winter A, Rabourdin-Combe C, Mehtali M, Moullier P, Darlix J-L, and Cosset F-L (2000) Characterization of novel safe lentiviral vectors derived from simian immunodeficiency virus (SIVmac251) that efficiently transduce mature human dendritic cells. Gene Ther 7:1613-1623
109. Nguyen T, Pages J-C, Farge D, Briand P, and Weber A (1998) Amphotropic retroviral vectors displaying hepatocyte growth factor-envelope fusion proteins improve transduction efficiency of primary hepatocytes. Hum Gene Ther 9:2469-2479
110. Nilson BHK, Morling FJ, Cosset F-L, and Russell SJ (1996) Targeting of retroviral vectors through protease-substrate interactions. Gene Ther. 3:280-286
111. Ohno K, Sawai K, Iijima Y, Levin B, and Meruelo D (1997) Cell-specific targeting of Sindbis virus vectors displaying IgG-binding domains of protein A. Nat Biotechnol 15:763-767
112. Ott DE (1997) Cellular proteins in HIV virions. Rev Med Virol 7:167-180
113. Overbaugh J, Miller AD, and Eiden MV (2001) Receptors and entry cofactors for retroviruses include single and multiple transmembrane-spanning proteins as well as newly described glycophosphatidylinositol-anchored and secreted proteins. Microbiol Mol Biol Rev 65:371-89
114. Patterson SM, Swainsbury R, and Routledge EG (1999) Antigen-specific membrane fusion mediated by the haemagglutinin protein of influenza A virus: separation of attachment and fusion functions on different molecules. Gene Ther 6:694-702
115. Peng K-W, Vile RG, Cosset F-L, and Russell SJ (1999) Selective transduction of protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors. Gene Ther 6:1552-1557
116. Peng KW, F.J. Morling, Cosset F-L, Murphy G, and Russell SJ (1997) A gene delivery system activatable by disease-associated matrix metalloproteinases. Hum Gene Ther 8:729-738
117. Peng KW, Morling FJ, Cosset F-L, and Russell SJ (1998) A retroviral gene delivery system activatable by plasmin. Tumor Targeting 3:112-120
118. Peng KW, Pham L, Ye H, Zufferey R, Trono D, Cosset F-L, and Russell SJ (2001) Organ distribution of gene expression after intravenous infusion of targeted and untargeted lentiviral vectors. Gene Ther 8:1456-63
119. Pickl WF, Pimentel-Muinos FX, and Seed B (2001) Lipid rafts and pseudotyping. J Virol 75:7175-83
120. Pinter A, Kopelman R, Li Z, Kayman SC, and Sanders DA (1997) Localization of the labile disulfide bond between SU and TM of the murine leukemia virus envelope protein complex to a highly conserved CWLC motif in SU that resembles the active-site sequence of thiol-disulfide exchange enzymes. J Virol 71:8073-8077
121. Pizzato M, Blair ED, Fling M, Kopf J, Tomassetti A, Weiss RA, and Takeuchi Y (2001) Evidence for non-specific adsorption of targeted retrovirus vector particles to cells. Gene Ther 8:1088-96
122. Pizzato M, Marlow SA, Blair ED, and Takeuchi Y (1999) Initial binding of murine leukemia virus particles to cells does not require specific Env-receptor interaction. J Virol 73:8599-611
123. Porter CD (2002) Cationic liposomes for envelope-independent retroviral transduction and enhancement of fusion-deficient targeted viruses. Gene Ther. in press
124. Porter CD, Collins MKL, Tailor CS, Parker MH, Cosset F-L, Weiss RA, and Takeuchi Y (1996) Comparison of efficiency of infection of human gene therapy target cells via four different retroviral receptors. Hum Gene Ther 7:913-919
125. Porter CD, Lukacs KV, Box G, Takeuchi Y, and Collins MK (1998) Cationic liposomes enhance the rate of transduction by a recombinant retroviral vector in vitro and in vivo. J Virol 72:4832-40
126. Ragheb JA, and Anderson WF (1994) pH-independent murine leukemia virus ecotropic envelope-mediated cell fusion: Implications for the role of the R peptide and p12E TM in viral entry. J Virol 68:3220-3231
127. Reeves JD, and Schulz TF (1997) The CD4-independent tropism of human immunodeficiency virus type 2 involves several regions of the envelope protein and correlates with a reduced activation threshold for envelope-mediated fusion. J Virol 71:1453-1465
128. Rein A, Mirro J, Haynes JG, Ernst SM, and Nagashima K (1994) Function of the cytoplasmic domain of a retroviral transmembrane protein: p15E-p2E cleavage activates the membrane fusion capability of the murine leukemia virus env protein. J Virol 68:1773-1781
129. Rodrigues P, and Heard JM (1999) Modulation of phosphate uptake and amphotropic murine leukemia virus entry by posttranslational modifications of PIT-2. J. Virol.:3789-3799
130. Rothenberg SM, Olsen MN, Laurent LC, Crowley RA, and Brown PO (2001) Comprehensive mutational analysis of the Moloney murine leukemia virus envelope protein. J Virol 75:11851-62
131. Roux P, Jeanteur P, and Piechaczyk M (1989) A versatile approach to the targeting of specific cell types by retroviruses. Proc Natl Acad Sci USA 86:9079-9083
132. Russell SJ, and Cosset F-L (1999) Modifying the host range properties of retroviral vectors. J Gene Med 1:300-311
133. Russell SJ, Hawkins RE, and Winter G (1993) Retroviral vectors displaying functional antibody fragments. Nucl Acids Res 21:1081-1085
134. Salmon P, Nègre D, Trono D, and Cosset F-L (2000) A chimeric GALV-derived envelope glycoprotein harboring the cytoplasmic tail of MLV envelope efficiently pseudotypes HIV-1 vectors. J Gen Med 2 (suppl):23
135. Sanders DA (2000) Sulfhydryl involvement in fusion mechanisms. In "Fusion of biological membranes and related problems" (Hilderson and Fuller, eds.), pp. 483-514. Kluwer Academic/Plenum Publishers, New York
136. Sandrin V, Boson B, Salmon P, Gay W, Nègre D, Grand RL, Trono D, and Cosset F-L (2002) Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and non-human primates. Blood 100:823-832
137. Schneider RM, Medvedovska Y, Voelker B, Chadwick MP, Russell SJ, Cichutek K, and Buchholz CJ (2002) Matrix metalloprotease substrates selected in living human cells using retroviral peptide libraries. in press
138. Schnierle BS, Stitz J, Bosch V, Nocken F, Merget-Millitzer H, Engelstadter M, Kurth R, Groner B, and Cichutek K (1997) Pseudotyping of murine leukemia virus with the envelope glycoproteins of HIV generates a retroviral vector with specificity of infection for CD4-expressing cells. Proc Natl Acad Sci USA 94:8640-8645
139. Schwartz AL (1995) Receptor cell biology: receptor-mediated endocytosis. Pediatr Res 38:835-843
140. Seganti L, Superti F, Girmenia C, Melucci L, and Orsi N (1986) Study of receptors for vesicular stomatitis virus in vertebrate and invertebrate cells. Microbiologica 9:259-67
141. Sharkey CM, North CL, Kuhn RJ, and Sanders DA (2001) Ross River virus glycoprotein-pseudotyped retroviruses and stable cell lines for their production. J Virol 75:2653-9
142. Sharma S, Miyanohara A, and Friedmann T (2000) Separable mechanisms of attachment and cell uptake during retrovirus infection. J Virol 74:10790-5
143. Sharma S, Murai F, Miyanohara A, and Friedmann T (1997) Noninfectious virus-like particles produced by Moloney murine leukemia virus-based retrovirus packaging cells deficient in viral envelope become infectious in the presence of lipofection reagents. Proc Natl Acad Sci U S A 94:10803-8
144. Skehel JJ, and Wiley DC (2000) Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu. Rev. Biochem. 69:531-69
145. Smit JM, Bittman R, and Wilschut J (1999) Low-pH-dependent fusion of Sindbis virus with receptor-free cholesterol- and sphingolipid-containing liposomes. J. Virol. 73:8476-8484
146. Snitkovsky S, Niederman T, Mulligan R, and Young J (2001) Targeting avian leukosis virus subgroup A vectors by using a TVA-VEGF bridge protein. J Virol 75:1571-5
147. Snitkovsky S, Niederman TM, Carter BS, Mulligan RC, and Young JA (2000) A TVA-single-chain antibody fusion protein mediates specific targeting of a subgroup A avian leukosis virus vector to cells expressing a tumor-specific form of epidermal growth factor receptor. J Virol 74:9540-5
148. Snitkovsky S, and Young JA (1998) Cell-specific viral targeting mediated by a soluble retroviral receptor-ligand fusion protein. Proc Natl Acad Sci USA 95:7063-7068
149. Snitkovsky S, and Young JA (2002) Targeting Retroviral Vector Infection to Cells That Express Heregulin Receptors Using a TVA-Heregulin Bridge Protein. Virology 292:150-5
150. Somia NV, Zoppé M, and Verma IM (1995) Generation of targeted retroviral vectors by using single-chain variable fragment: an approach to in vivo gene delivery. Proc Natl Acad Sci USA 92:7570-7574
151. Spiegel M, Bitzer M, Schenk A, Rossmann H, Neubert WJ, Seidler U, Gregor M, and Lauer U (1998) Pseudotype formation of Moloney Murine leukemia virus with Sendai virus glycoprotein F. J Virol 72:5269-5302
152. Stitz J, Buchholz C, Engelstadter M, Uckert W, Bloemer U, Schmitt I, and Cichutek K (2000) Lentiviral vectors pseudotyped with envelope glycoproteins derived from gibbon ape leukemia virus and murine leukemia virus 10A1. Virology 273:16-20
153. Sung VM, and Lai MM (2002) Murine retroviral pseudotype virus containing hepatitis B virus large and small surface antigens confers specific tropism for primary human hepatocytes: a potential liver-specific targeting system. J Virol 76:912-7
154. Suomalainen M, and Garoff H (1994) Incorporation of homologous and heterologous proteins into the envelope of Moloney murine leukemia virus. J Virol 68:4879-4889
155. Swanstrom R, and Wills JW (1997) Synthesis, assembly, and processing of viral proteins. In "Retroviruses" (J M Coffin, S H Hughes and H
156. Takeuchi Y, Simpson G, Vile R, Weiss R, and Collins M (1992a) Retroviral pseudotypes produced by rescue of moloney murine leukemia virus vector by C-type, but not D-type, retroviruses. Virology 186:792-794
157. Thaler S, and Schnierle BS (2001) A packaging cell line generating CD4-specific retroviral vectors for efficient gene transfer into primary human T-helper lymphocytes. Mol Ther 4:273-9
158. Ugolini S, Mondo I, and Sattentau QJ (1999) HIV-1 attachment: another look. Trends Microbiol 7:144-9
159. Valsesia-Wittmann S (2001) Role of chimeric murine leukemia virus env beta-turn polyproline spacers in receptor cooperation. J Virol 75:8478-86
160. Valsesia-Wittmann S, Drynda A, Deleage G, Aumailley M, Heard J-M, Danos O, Verdier G, and Cosset F-L (1994) Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors. J. Virol. 68:4609-4619
161. Valsesia-Wittmann S, Morling FJ, Hatziioannou T, Russell SJ, and Cosset F-L (1997) Receptor co-operation in retrovirus entry: recruitment of an auxilliary entry mechanism after retargeted binding. EMBO J 16:1214-1223
162. Valsesia-Wittmann S, Morling FJ, Nilson BHK, Takeuchi Y, Russell SJ, and Cosset F-L (1996) Improvement of retroviral retargeting by using amino acid spacers between an additional binding domain and the N terminus of Moloney murine leukemia virus SU. J. Virol. 70:2059-2064
163. Vincent MJ, Melsen LR, Martin AS, and Compans RW (1999) Intracellular interaction of simian immunodeficiency virus Gag and Env proteins. J Virol 73:8138-44
164. Walker SJ, Pizzato M, Takeuchi Y, Devereux S (2002) Heparin binds to murine leukemia virus and inhibits Env-independent attachment and infection. J Virol 76:6909-18
165. Wensel DL, Li W, Cunningham JM (2003) A virus-virus interaction circumvents the virus receptor requirement for infection by pathogenic retroviruses. Virol 77:3460-9
166. Wilson C, Reitz MS, Okayama H, and Eiden MV (1989) Formation of infectious hybrid virions with gibbon ape leukemia virus and human T-cell leukemia virus retroviral envelope glycoproteins and the gag and pol proteins of Moloney murine leukemia virus. J Virol 63:2374-8
167. Wool-Lewis RJ, and Bates P (1998) Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines. J Virol 72:3155-3160
168. Wu BW, Cannon PM, Gordon EM, Hall FL, and Anderson WF (1998) Characterization of the proline-rich region of murine leukemia virus envelope protein. J Virol 72:5383-5391
169. Wu BW, Lu J, Gallaher TK, Anderson WF, and Cannon PM (2000) Identification of regions in the Moloney murine leukemia virus SU protein that tolerate the insertion of an integrin-binding peptide. Virology 269:7-17
170. Wyma DJ, Kotov A, and Aiken C (2000) Evidence for a stable interaction of gp41 with Pr55(Gag) in immature human immunodeficiency virus type 1 particles. J Virol 74:9381-7
171. Yajima T, Kanda T, Yoshiike K, and Kitamura Y (1998) Retroviral vector targeting human cells via c-Kit-stem cell factor interaction. Hum Gene Ther 10:779-787
172. Zhao Y, Lee S, and Anderson WF (1997) Functional interactions between monomers of the retroviral envelope protein complex. J Virol 71:6967-6972
173. Zhao Y, Zhu L, Lee S, Li L, Chang E, Soong NW, Douer D, and Anderson WF (1999) Identification of the block in targeted retroviral-mediated gene transfer. Proc Natl Acad Sci U S A 96:4005-4010